BioPharma APAC: R‑biolin matches Novolin® R in pre‑clinical tests, gears up for 50× scale‑up and human trials
BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.
FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products
Bioequivalence confirmed: Pre‑clinical data demonstrate pharmacokinetic and pharmacodynamic parity with Novolin® R.
WIRED: Can a tiny biotech make insulin dirt‑cheap?
WIRED’s in‑depth feature brings rBIO’s mission to a mainstream tech audience, explaining how the company’s R‑biolin biosimilar could shake up a century‑old insulin supply chain and drive down costs for the 8 million US insulin‑dependent patients.